Randomised trials in ovarian cancer: trial design considerations

被引：6
|
作者：
Brady, MF
Thigpen, JT
Vermorken, JB
Parmar, MKB
机构：
[1] Roswell Pk Canc Inst, GOG Stat Off, Buffalo, NY 14263 USA
[2] Univ Mississippi, Sch Med, Dept Med, Jackson, MS 39216 USA
[3] Univ Antwerp Hosp, Dept Med Oncol, Edegem, Belgium
[4] MRC, Canc Trials Off, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 1999年 / 10卷
关键词：
end point selection; progression-free survival; response; survival; trial size;
D O I：
10.1023/A:1008319704310
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Randomised clinical trials are considered the definitive source of evidence for guiding decisions in clinical practice. The concept of a clinical trial is based on sound scientific, ethical, and practical principles. The strength of evidence that an individual trial provides is assessed on the manner in which these principles are incorporated into the design and execution of the trial. Since the way these principles are incorporated into a trial is judgmental, the strength of evidence from an individual trial is a matter of degree. The purpose of this paper is to present some of the scientific, ethical and practical considerations surrounding the selection of endpoints and determination of sample size for trials in ovarian cancer.
引用
收藏
页码：75 / 82
页数：8
相关论文
共 50 条
  • [31] Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials
    Lin, Timothy A.
    Sherry, Alexander D.
    Ludmir, Ethan B.
    SEMINARS IN RADIATION ONCOLOGY, 2023, 33 (04) : 429 - 437
  • [32] Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients
    Sehouli, Jalid
    Fotopoulou, Christina
    Erol, Edibe
    Richter, Rolf
    Reuss, Alexander
    Mahner, Sven
    lauraine, Eric Pujade
    Kristensen, Gunnar
    Herrstedt, Joern
    du Bois, Andreas
    Pfisterer, Jacobus
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (07) : 825 - 832
  • [33] Considerations for open-label randomized clinical trials: Design, conduct, and analysis
    Higgins, Karen M.
    Levin, Gregory
    Busch, Robert
    CLINICAL TRIALS, 2024, 21 (06) : 681 - 688
  • [34] Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials
    Doussau, Adelaide
    Agarwal, Isha
    Fojo, Tito
    Tannock, Ian F.
    Grady, Christine
    CLINICAL TRIALS, 2021, 18 (06) : 690 - 698
  • [35] Clinical Trials in Elderly Ovarian Cancer Patients - Does It Make Sense?
    Kuhn, Walther
    ONKOLOGIE, 2012, 35 (03): : 73 - 74
  • [36] Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
    Yuan, Peng
    Hu, Xichun
    Sun, Tao
    Li, Wei
    Zhang, Qingyuan
    Cui, Shude
    Cheng, Ying
    Ouyang, Quchang
    Wang, Xiaojia
    Chen, Zhendong
    Hiraiwa, Masahide
    Saito, Kenichi
    Funasaka, Setsuo
    Xu, Binghe
    EUROPEAN JOURNAL OF CANCER, 2019, 112 : 57 - 65
  • [37] Effects and feasibility of a multi-disciplinary orientation program for newly registered cancer patients: design of a randomised controlled trial
    Chan, Raymond
    Webster, Joan
    Bennett, Linda
    BMC HEALTH SERVICES RESEARCH, 2009, 9
  • [38] The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
    de Boniface, Jana
    Ahlgren, Johan
    Andersson, Yvette
    Bergkvist, Leif
    Frisell, Jan
    Lundstedt, Dan
    Olofsson Bagge, Roger
    Ryden, Lisa
    Sund, Malin
    Christiansen, Peer
    Christiansen, Peer
    Filtenborg Tvedskov, Tove
    Offersen, Birgitte Vrou
    Reimer, Toralf
    Kuehn, Thorsten
    Kontos, Michalis
    Gentilini, Oreste
    Reitsamer, Roland
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (01) : 167 - 176
  • [39] Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: Considerations for drug repurposing
    Regulska, Katarzyna
    Gieremek, Paulina
    Michalak, Marcin
    Kolenda, Tomasz
    Janiczek-Polewska, Marlena
    Kozlowska-Maslon, Joanna
    Cybulski, Zefiryn
    Stanisz, Beata J.
    DRUG DISCOVERY TODAY, 2025, 30 (04)
  • [40] Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
    Matulonis, Ursula A.
    Oza, Amit M.
    Ho, Tony W.
    Ledermann, Jonathan A.
    CANCER, 2015, 121 (11) : 1737 - 1746
12345